Medscape: Analysis boosts Fluvoxamine for COVID, but what's the evidence?
UC expert says research may be useful, but more trials are needed
A report published recently in JAMA Open Network finds there's a strong likelihood that the antidepressant fluvoxamine (Luvox) may moderately lower rates of hospitalization due to COVID-19 in unvaccinated patients. However, outside experts cited by Medscape differ over whether the evidence from just three studies is strong enough to warrant adding the drug to the COVID-19 treatment arsenal. One of those experts sources is Carl Fichtenbaum, MD, of the Division of Infectious Diseases at the UC College of Medicine.
Carl Fichtenbaum, MD, of the Division of Infectious Diseases at the UC College of Medicine/Photo/Joe Fuqua II/UC Creative + Brand
"This research might be valuable, but the jury remains out until several other adequately powered and designed trials are completed," said Fichtenbaum, who's familiar with the findings. "I'm not sure how useful this is given we have several antiviral agents available. Why would we choose this over Paxlovid, remdesivir, or molnupiravir?"
According to Fichtenbaum, researchers began focusing on fluvoxamine after case reports about patients improving while on the medication. This led to further interest, he said, boosted by the drug's known ability to dampen the immune system.
Lead photo/Science News
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's medical, graduate and undergraduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
So do ‘sin taxes’ curb harmful behavior?
March 9, 2025
The Ohio Capital Journal reports that Ohio Gov. Mike DeWine is proposing to create a child tax credit and to pay for it with increased 'sin taxes' on tobacco. According to one analysis, the tax credit is expected to produce big gains for the state. Michael Jones, PhD, associate professor in the Lindner College of Business, weighs in on the effectiveness of 'sin taxes.'
Message from President Pinto: Moving forward together
March 7, 2025
Message from President Pinto to UC Community: Moving forward together
New clinical trial aims to optimize pain management and reduce...
March 7, 2025
MSN highlighted a new University of Cincinnati Cancer Center clinical trial aimed to optimize pain management and reduce the need for opioids after mastectomy procedures.